Overview

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Status:
Recruiting

Trial end date:
2024-03-26

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Loxo Oncology, Inc.

Collaborator:

Eli Lilly and Company